Puromycin Aminonucleoside: Gold-Standard Nephrotoxic Agent for Podocyte Injury Modeling

Executive Summary: Puromycin aminonucleoside (CAS 58-60-6) is the aminonucleoside moiety of puromycin and is used as a highly reproducible nephrotoxic agent to induce podocyte injury and nephrotic syndrome in animal models (APExBIO). It disrupts podocyte microvilli and foot-process structures, leading to proteinuria and glomerular lesions that resemble focal segmental glomerulosclerosis (FSGS) (Bridgene). Uptake by PMAT-expressing cells is pH dependent and shows cytotoxicity with defined IC₅₀ values. Solubility in DMSO, ethanol, and water is well characterized, enabling flexible experimental protocols. Puromycin aminonucleoside enables precise dissection of renal pathophysiology and is a critical reagent for nephrology research (Coagulation Factor II).

Biological Rationale

Puromycin aminonucleoside is the prototype compound for modeling nephrotic syndrome and podocyte injury. Podocytes are specialized epithelial cells crucial for maintaining the glomerular filtration barrier in the kidney. Injury to podocytes leads to proteinuria, a cardinal feature of nephrotic syndrome and many forms of glomerular disease, including focal segmental glomerulosclerosis (FSGS). Animal models using puromycin aminonucleoside allow controlled induction of podocyte injury, enabling mechanistic studies and preclinical therapeutic screening (Bridgene).

Mechanism of Action of Puromycin aminonucleoside

Puromycin aminonucleoside exerts its nephrotoxic effects primarily by targeting podocytes. In vitro, it reduces microvilli and disrupts cytoskeletal organization, leading to effacement of foot processes. These cellular changes compromise the integrity of the glomerular filtration barrier, resulting in increased protein leakage into the urine (proteinuria). In vivo, administration in rats produces a phenotype that closely mirrors human FSGS, including podocyte detachment, glomerular scarring, and lipid accumulation in mesangial cells. Uptake of puromycin aminonucleoside is mediated by organic cation transporters, notably PMAT, and is strongly pH-dependent—being fourfold higher at pH 6.6 than at pH 7.4 in PMAT-transfected cells. Cytotoxicity in MDCK cells is quantifiable: IC₅₀ values are 48.9 ± 2.8 μM (vector) and 122.1 ± 14.5 μM (PMAT-expressing) (APExBIO).

Evidence & Benchmarks

• Puromycin aminonucleoside is the reference agent for inducing reproducible podocyte injury and proteinuria in rat models of nephrotic syndrome (Bridgene).
• In vitro treatment disrupts podocyte microvilli and cytoskeletal structure, as visualized by electron microscopy (Coagulation Factor II).
• FSGS-like lesions and lipid accumulation in mesangial cells are recapitulated in vivo, validating translational relevance (Big Endothelin-1).
• PMAT-mediated uptake is pH-sensitive, with a fourfold increase at pH 6.6 versus pH 7.4 in PMAT-expressing MDCK cells (APExBIO).
• Solubility is ≥14.45 mg/mL in DMSO, ≥29.4 mg/mL in ethanol, and ≥29.5 mg/mL in water with gentle warming (APExBIO).

This article extends the mechanistic precision and workflow integration aspects discussed in 'Puromycin Aminonucleoside: Gold-Standard Podocyte Injury ...' by providing new insights into transporter-specific uptake and quantitative cytotoxicity. For further discussion on translational and protocol strategies, see 'Puromycin Aminonucleoside: Precision Podocyte Injury Mode...', which this article updates by incorporating latest solubility and workflow data.

Applications, Limits & Misconceptions

Puromycin aminonucleoside is widely used for:

• Modeling proteinuria and nephrotic syndrome in rodents.
• Investigating podocyte cytoskeleton disruption and molecular mechanisms of glomerular filtration barrier breakdown.
• Quantifying cytotoxicity and transporter-specific compound uptake in cell lines.
• Validating new therapies targeting FSGS and nephrotic syndrome.

Common Pitfalls or Misconceptions

• Puromycin aminonucleoside does not induce nephrotic syndrome in all animal species; susceptibility varies (e.g., mice are less sensitive than rats).
• It is not suitable for chronic or multi-factorial models of glomerular disease beyond acute podocyte injury.
• Cytotoxicity is transporter- and pH-dependent; results cannot be generalized across all cell types or assay conditions.
• Long-term storage of aqueous solutions is not recommended due to compound instability; use immediately after preparation.
• It does not model all aspects of human nephrotic syndrome, such as immune-mediated mechanisms or genetic etiologies.

Workflow Integration & Parameters

APExBIO’s Puromycin aminonucleoside (A3740) is supplied for research use with defined storage and handling guidelines. Stock solutions are stable below -20°C for several months. Working solutions should be freshly prepared and used promptly. Solubility parameters: ≥14.45 mg/mL in DMSO, ≥29.4 mg/mL in ethanol, ≥29.5 mg/mL in water with gentle warming. Shipping is on blue ice for small molecules; dry ice for nucleotides. For in vivo studies, rats are typically administered single or multiple intraperitoneal injections (dose range: 10–150 mg/kg, species and protocol dependent). In vitro, cytotoxicity assays should control for transporter expression and pH. See the product page for full technical details and batch-specific documentation.

Conclusion & Outlook

Puromycin aminonucleoside remains the gold standard for modeling podocyte injury, proteinuria, and FSGS-like lesions in renal research. Its reproducibility, clear mechanism, and compatibility with advanced in vitro and in vivo systems underpin its continued use in nephrology and renal pathology research. Future advances may focus on transporter-targeted delivery, chronic disease modeling, and the integration of genetic models with chemical induction for deeper mechanistic insight.